CARLSBAD, Calif.--A new Invitrogen technology that can be used to rapidly clone and express genes will expedite functional validation to keep pace with strides being made in structural genomics and DNA chip-based expressional analysis, according to Invitrogen CEO Lyle Turner. The proprietary technology, amenable to any gene collection, was first tested using the yeast genome. Since October 1997, Invitrogen has cloned 6,000 and expressed 1,000 yeast genes.
Subsequently, Invitrogen launched GeneStorm expression-ready yeast clones, the first in a series of products designed to assist life science researchers design functional validation assays to be applied to drug discovery. The company said it expects to launch its first line of GeneStorm human expression-ready clones this spring.